What's Going On With Eli Lilly and Company Shares Friday
Portfolio Pulse from Dylan Berman
Eli Lilly and Company (NYSE:LLY) shares are trading lower on Friday despite promising results from its SUMMIT phase 3 clinical trial. The company is set to release its Q2 2024 earnings on Aug. 8, with analysts estimating revenue of $9.9 billion and EPS of $2.7. The trial showed that tirzepatide reduced heart failure events by 38% and caused a 15.7% weight loss in patients.
August 02, 2024 | 2:39 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Eli Lilly shares are trading lower despite positive results from its SUMMIT phase 3 clinical trial. The company is set to release its Q2 2024 earnings on Aug. 8, with analysts estimating revenue of $9.9 billion and EPS of $2.7.
Despite the positive clinical trial results, the stock is trading lower, possibly due to market anticipation of the upcoming earnings report. The earnings report could provide further direction for the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100